ENKASTIM™

N/A

Report date: 2024/04/24 14:56:17

Base Information

Drug NameENKASTIM™
Drug Alias NameHeat shock protein 70 peptide activated natural killer cellsActivated autologous NK cellsHSP70 peptide activated natural killer cellsEnkastim-ivEnkastim-ev +[8] 
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapyCell and gene therapy > Cell therapy > Source of cells > PMBC-derived
Mechanisms of ActionHSP70 heat-shock proteins modulators
TargetsHSP70 heat-shock proteins
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesMultimmune
China Registration ClassN/A

Develop Information

Active CompaniesAlphageneron Pharmaceuticals Inc
Inactive CompaniesTechnical University MunichMultimmune
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A